Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
Protein Name: | ABCB1 |
Gene Name: | ABCB1 |
Protein Full Name: | Multidrug resistance protein 1 |
Alias: | ABC20; ATP-binding cassette sub-family B member 1; ATP-binding cassette, sub-family B (MDR/TAP) member 1; CD243; CD243 antigen; CLCS; GP170; MDR1; MDR3; P-glycoprotein 1; P-gp; PGY1 |
Mass (Da): | 141479 |
Number AA: | 1280 |
UniProt ID: | P08183 |
Locus ID: | 5243 |
COSMIC ID: | ABCB1 |
Gene location on chromosome: | 7q21.2 |
Cancer protein type: | OP |
Effect of cancer mutation on protein: | GAIN |
Effect of active protein on cancer: | PROMOTES |
Number of cancer specimens: | 19689 |
Percent of cancer specimens with mutations: | 1.97 |
Found in amplified chromosomal regions in human cancers: | The genomic amplification of ABCB1 appears as extrachromosomic "double-minute chromosomes" (DM) or intrachromosomic "homogeneous staining regions" (HSR). |
Normal role description: | ABCB1 is an energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells. Elevated levels of ABCB1 may contribute to the resistance of cancer cells such as leukemia cells to drugs. Tumour cells resistance to a wide variety of antineoplasic agents: doxorubicin, daunorubicin, vinblastine, vincristine, colchicine, actinomycine D, etoposide, tenoposide, mitoxantrone, homoharringtonine; this phenomenon is named "multidrug resistance" (MDR); P-glycoprotein is the main protein responsible for the MDR phenotype. |
Commentary on involvement of protein in cancer: | Mis-sense and non-sense mutations occur in some ovarian cancers. However, over-expression of the wild-type form of ABCB1 may contribute to cancer development by increasing chemotherapy drug resistance. |